Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASMB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAssembly Biosciences reports Q1 2026 financial results
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for the quarter ended March 31, 2026. Detailed figures are contained in the attached exhibit rather than the 8-K body.
Item 2.02 verify on EDGAR → -
medium
Press release dated May 7, 2026 attached as Exhibit 99.1. The 8-K filing itself does not provide specific financial metrics or commentary on performance.
Item 9.01 verify on EDGAR →
Summary
Assembly Biosciences filed an 8-K on May 7, 2026 to announce its first quarter 2026 financial results. The filing follows standard practice for quarterly earnings disclosures, with the company attaching a press release as an exhibit rather than including detailed financial information in the 8-K body itself. This is a routine quarterly reporting event that biotech investors should expect four times per year.
For retail shareholders, the key information will be in the attached press release (Exhibit 99.1), which should detail revenue, expenses, cash position, and any updates on the company's clinical pipeline or business development activities. Investors should review the full press release to assess the company's financial health and progress on its hepatitis B and microbiome programs. Watch for any guidance updates or commentary on cash runway in the complete disclosure.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Assembly Biosciences filed an 8-K attaching a press release dated May 7, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit | Number | Description | 99.1 | Press Release dated May 7, 2026.
The company attached a press release dated May 7, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.
Event · Item 2.02 — Results of Operations and Financial Condition
Assembly Biosciences announced Q1 2026 financial results via press release on May 7, 2026.
Added in current filing · verify on EDGAR →
On May 7, 2026, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the attached press release (Exhibit 99.1) which contains the detailed results.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify